Digitoxin improves outcomes in heart failure with reduced ejection fraction
1. Among patients with symptomatic chronic heart failure already on guideline-directed medical therapy (GDMT), digitoxin lowered all-cause mortality and hospital...
Similar outcomes between lactated Ringer’s and normal saline for hospitalized patients
1. Among randomized hospitalized patients in this trial, routine use of lactated Ringer’s (LR) solution did not reduce the risk...
Finerenone with empagliflozin beneficial for managing CKD and type 2 diabetes
1. Among patients with both chronic kidney disease (CKD) and type 2 diabetes (T2D) already on a renin-angiotensin system (RAS)...
Weekly basal insulin efsitora effective for managing type 2 diabetes
1. In patients with type 2 diabetes mellitus (T2DM) who had not previously been on insulin therapy, once-weekly fixed-dose insulin...
Pembrolizumab improves survival in locally advanced head and neck cancer
1. Among patients with locally advanced head and neck squamous-cell carcinoma (HNSCC), neoadjuvant and adjuvant pembrolizumab improved event-free survival compared...
Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
1. In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the forced vital...
Inebilizumab improves outcome in patients generalized myasthenia gravis
1. In patients with myasthenia gravis (MG) who had anti-acetylcholine receptor antibodies or anti-muscle-specific kinase antibodies, intravenous inebilizumab reduced disease...
Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
1. In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, sotatercept reduced...
Delayed alteplase has clinical benefits in posterior circulation stroke outcomes
1. In this randomized controlled trial of patients with posterior circulation stroke not for thrombectomy, treatment with alteplase 4.5 to...
Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis
1. In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral tolebrutinib reduced the risk...
